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Background: Clinical studies of the associations of vitamin E with lung function have reported conflicting results.
However, these reports primarily examine the α-tocopherol isoform of vitamin E and have not included the isoform
γ-tocopherol which we recently demonstrated in vitro opposes the function of α-tocopherol. We previously
demonstrated, in vitro and in animal studies, that the vitamin E isoform α-tocopherol protects, but the isoform
γ-tocopherol promotes lung inflammation and airway hyperresponsiveness.
Methods: To translate these findings to humans, we conducted analysis of 4526 adults in the Coronary Artery
Risk Development in Young Adults (CARDIA) multi-center cohort with available spirometry and tocopherol data in
blacks and whites. Spirometry was obtained at years 0, 5, 10, and 20 and serum tocopherol was from years 0, 7
and 15 of CARDIA.
Results: In cross-sectional regression analysis at year 0, higher γ-tocopherol associated with lower FEV1 (p = 0.03
in blacks and p = 0.01 in all participants) and FVC (p = 0.01 in blacks, p = 0.05 in whites, and p = 0.005 in all
participants), whereas higher α-tocopherol associated with higher FVC (p = 0.04 in blacks and whites and p = 0.01
in all participants). In the lowest quartile of α-tocopherol, higher γ-tocopherol associated with a lower FEV1
(p = 0.05 in blacks and p = 0.02 in all participants). In contrast, in the lowest quartile of γ-tocopherol, higher
α-tocopherol associated with a higher FEV1 (p = 0.03) in blacks. Serum γ-tocopherol >10 μM was associated
with a 175–545 ml lower FEV1 and FVC at ages 21–55 years.
Conclusion: Increasing serum concentrations of γ-tocopherol were associated with lower FEV1 or FVC, whereas
increasing serum concentrations of α-tocopherol was associated with higher FEV1 or FVC. Based on the prevalence of
serum γ-tocopherol >10 μM in adults in CARDIA and the adult U.S. population in the 2011 census, we expect that the
lower FEV1 and FVC at these concentrations of serum γ-tocopherol occur in up to 4.5 million adults in the population.
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There are seemingly conflicting results in clinical stud-
ies with vitamin E. As we discuss in a recent perspec-
tive [1] and recent reviews [2-4], conflicting outcomes
in clinical studies and differences in prevalence of aller-
gic disease among countries may, at least in part, reflect
differences in the serum levels of γ-tocopherol. There* Correspondence: j-cook-mills@northwestern.edu
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unless otherwise stated.are four tocopherol isoforms of vitamin E: α-tocopherol,
γ-tocopherol, β-tocopherol and δ-tocopherol. The vitamin
E isoforms, α-tocopherol and γ-tocopherol are the most
abundant in diet and tissues, and α-tocopherol is the most
studied. α-tocopherol and γ-tocopherol differ by one me-
thyl group and, at equal molar concentrations, have a rela-
tively similar capacity to scavenge reactive oxygen species
(ROS) [5,6]. In contrast to α-tocopherol, γ-tocopherol also
reacts with reactive nitrogen species [7] and may be bene-
ficial for inflammation with increases in reactive nitrogen
species such as neutrophilic inflammation [8,9].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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α-tocopherol is about 10 fold higher than γ-tocopherol
in tissues due primarily to the preferential transfer of
α-tocopherol to lipid particles by liver α-tocopherol
transfer protein [10] and due to a higher rate of pro-
duction of γ-tocopherol metabolites for excretion [11].
In the U.S., the mean adult serum γ-tocopherol is about
5–7 μM, whereas European and other countries have a
2–6 fold lower serum γ-tocopherol concentration [1-4].
These differences in serum γ-tocopherol are consistent
with European diets rich in olive oil, which is low in γ-
tocopherol, and American diets rich in soy oil, which is
high in γ-tocopherol [1]. In contrast, the average serum
concentrations of α-tocopherol are similar among these
populations [1-4].
We have reported that, in mice, α-tocopherol supple-
mentation improves and γ-tocopherol supplementation
worsens eosinophilic lung inflammation and airway
hyperresponsiveness [12]. When treated with both α-
tocopherol and γ-tocopherol, γ-tocopherol ablates the
benefit of α-tocopherol [12]. In mechanistic studies, we
demonstrated that α-tocopherol inhibits and γ-tocopherol
increases leukocyte recruitment and the activation of pro-
tein kinase Cα (PKCα) during leukocyte recruitment
[12-14]. Moreover, we demonstrated that these tocoph-
erols directly bind to PKCα and that α-tocopherol is an
antagonist and γ-tocopherol is an agonist of PKCα [14].
However, it is not known whether these tocopherol iso-
forms have opposing associations with lung spirometry in
humans.
We hypothesized that in humans, serum α-tocopherol
and γ-tocopherol have opposing associations with spiro-
metric parameters and that there is an association of to-
copherols with these parameters when the concentration
of the opposing tocopherol is low and causing the least
competing opposing effects [1]. To test these hypotheses,
we analyzed a database with existing data for α-tocopherol,
γ-tocopherol and spirometry in a large cohort of 5114
participants with 20 years follow-up.
Results
Participant description at year 0 examination
We determined whether there are opposing associations
of α-tocopherol and γ-tocopherol with the spirometry
parameters FEV1, FVC, and FEV1/FVC in humans using
the CARDIA study with 20 years participant follow-up
and existing data for spirometry and tocopherol isoforms.
Participant characteristics are in Table 1. By design for
CARDIA, the study had similar numbers of males and
females of each race. The mean serum α-tocopherol
concentration was lower and the mean γ-tocopherol
concentration was higher in black compared to white
participants at study year 0 (Table 2). This is consistent
with previous reports [15,16]. Due to racial differencesin tocopherol concentrations, and because there are
known race-based differences in spirometric parameters
[17], we stratified the dataset by race. Also, because fe-
males and males are known to differ in spirometric pa-
rameters [17], the analysis included adjustments for
gender.
γ-tocopherol and α-tocopherol have opposing associations
with spirometry parameters at year 0 examination
The cross-sectional, multivariable linear regressions ex-
amined the association of α-tocopherol with spirometric
parameters and γ-tocopherol with spirometric parame-
ters. The data are presented as difference in parameter
analyzed per 10 μM tocopherol, as previously described
for association studies with tocopherol [18]. In the cross-
sectional analysis, higher serum γ-tocopherol was signifi-
cantly associated with lower FEV1 and FVC in blacks
(Table 3). In whites and in analysis of all participants,
there was a significant association of higher γ-tocopherol
with lower FVC (Table 3).
In contrast, to the inverse association of γ-tocopherol
with spirometry, α-tocopherol was positively associated
with FVC, suggesting opposing effects of the two tocoph-
erol isoforms in blacks, whites, and all participants (Table 3).
There was a positive association between α-tocopherol and
FEV1 in black participants and in all participants and then,
in whites, there was a trend for a positive association
(Table 3). In whites, the FEV1/FVC was inversely associated
with increasing serum α-tocopherol, although the beta
was very small (Table 3). In these analyses for Table 3,
the other tocopherol isoform is present at various con-
centrations with potentially opposing functions. Similar
opposing associations of the tocopherol isoforms with
spirometry were observed when the data analyses in-
cluded adjustments for the other tocopherol isoform
(Additional file 1: Table S1).
Association of tocopherol isoforms with spirometry when
the opposing tocopherol isoform is within its lowest
quartile
The data in Table 3 suggested that the tocopherol iso-
forms have opposing associations with spirometry. Fur-
thermore, in our mechanistic studies in vitro and in
animals, γ-tocopherol potently increases inflammation
and lung hyperresponsiveness when the α-tocopherol tis-
sue concentration is low but this effect of γ-tocopherol is
ablated when the α-tocopherol tissue concentration is ele-
vated through supplementation [12-14]. Therefore, we hy-
pothesized that there would be a significant association of
tocopherols with FEV1 when the concentration of the op-
posing tocopherol was low, causing the least competing
opposing effects. For this analysis, we used quartile ana-
lysis rather than α-tocopherol/γ-tocopherol ratios because
ratios would be the same when both tocopherol isoforms
Table 1 Participant characteristics (year 0 of the CARDIA study)
Blacks Whites Total P value
Number of participants 2289 (50.6%) 2237 (49.4%) 4526
Male 1032 (49.4%) 1057 (50.6%) 2089 0.14
Female 1257 (51.6%) 1180 (48.4%) 2437
Mean age, years (SD) 24.3 (3.8) 25.5 (3.4) 4526 <0.0001
Current smoker 782 (34.2%) 611 (27.3%) 1393 <0.0001
Past smoker 210 (9.2%) 397 (17.8%) 607
Non-smoker 1297 (56.7%) 1229 (54.9%) 2526
Ever reported asthma 493 (21.5%) 427 (19.1%) 920 0.04
BMI, kg/m2 (SD) 25.48 (5.63) 23.71 (4.05) 4526 <0.0001
FEV1 (liters) [2SD Range] 3.28 [1.90-4.66] 3.83 [2.30-5.36] 4526 <0.0001
% predicted FEV1 (SD) 98.2 (12.7) 97.6 (10.7) 4526 0.06
FVC (liters) [2 SD Range] 3.93 [2.21-5.66] 4.68 [2.67-6.69] 4526 <0.0001
% predicted FVC (SD) 101.0 (12.4) 100 (10.6) 4526 0.002
FEV1/FVC (%) 83.72 82.36 4526 <0.0001
Median household income (study year 5) $25,000-34,999 $35,000-49,999 3806 <0.0001
Years of education (SD) 13.03 (1.82) 14.59 (2.38) 4526 <0.0001
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and because we previously reported in mechanistic ani-
mal studies that there are dose dependent effects of
tocopherol isoforms on lung inflammation [12,13].
Consistent with our hypothesis, in blacks at the lowest
quartile of α-tocopherol, there was a significant nega-
tive association of FEV1 with increasing γ-tocopherol
(Table 4A). At all quartile concentrations of α-tocopherol
with the exception of quartile 2 in blacks for FEV1, the dir-
ection of FEV1 and FVC was decreasing with increasing
units of γ-tocopherol (Table 4). In whites, at the lowest
quartile of α-tocopherol, there was a trend for a nega-
tive association of FEV1 with increasing γ-tocopherol
(Table 4B). For analysis of all participants (Table 4C),
the negative beta for FEV1 with γ-tocopherol was great-
est at the lowest quartile of α-tocopherol and the nega-
tive beta for FVC with γ-tocopherol was greatest at the
lowest two quartiles of α-tocopherol (Table 4C).
Conversely and consistent with our hypothesis, at the
lowest quartile of γ-tocopherol, there was a significant posi-
tive association of FEV1 and a trend for a positive associ-
ation of FVC with increasing α-tocopherol in blacks
(Table 5A). In whites, at the lowest quartile of γ-tocopherol,
there was no association for α-tocopherol with FEV1 and
FVC (Table 5B). For analysis of all participants, there wasTable 2 Serum α-tocopherol (α-T) and γ-tocopherol (γ-T) leve
Blacks
N Mean (μM) SD (μM) SE (μM) Range (μM)
α-T 2289 19.71 5.28 0.11 7.57-59.39 22
γ-T 2289 5.11 2.40 0.05 0.14- 67.41 22also no association for α-tocopherol with FEV1 and FVC
(Table 5C). These data suggest that, for blacks and whites,
associations for α-tocopherol with spirometry may be influ-
enced by environmental or genetic differences that are not
known.
Modeling average γ-tocopherol concentrations for the
USA and European/Asian countries reveals a significantly
lower FEV1 and FVC in participants with highly-elevated
γ-tocopherol
Given the difference in γ-tocopherol concentrations
in Americans versus Western Europeans and Asians
(Additional file 1: Table S1) [1,4] and the lung hyper-
reponsiveness promoting effect of a 5-fold increase in
γ-tocopherol in our animal models [12,13], we determined
whether a 5-fold higher γ-tocopherol associates with lower
spirometry parameters in the CARDIA participants at
ages 21–55 (Figure 1). For the analysis, we defined a priori
a γ-tocopherol group to model the average Western
European plasma γ-tocopherol levels and two γ-tocopherol
groups to model the average USA plasma γ-tocopherol
levels. The average Western European γ-tocopherol levels
are 1–2 μM γ-tocopherol (Additional file 2: Table S2) [1]
and therefore the group that models the average Western
European plasma γ-tocopherol is 1–2 μM γ-tocopherol.ls (year 0 of the CARDIA study)
Whites
N Mean (μM) SD (μM) SE (μM) Range (μM) P value
37 22.68 6.69 0.14 5.73- 84.91 <0.0001
37 4.64 1.97 0.04 0.00- 27.02 <0.0001
Table 3 The association of α-tocopherol (α-T) and γ-tocopherol (γ-T) with lung spirometry (year 0 of the CARDIA study)
Lung
spirometry
BLACKSa WHITESa ALL PARTICIPANTSb
N βc SE 95% confidence interval P value N β SE 95% confidence interval P value N β SE 95% confidence interval P value
α-T 2289 2237 4526
FEV1 27.6 17.3 −6.3 to 61.6 0.11
# 5.5 13.7 −21.4 to 32.4 0.69 11.1 10.8 −10.1 to 32.3 0.30
FVC 40.4 19.7 1.9 to 78.9 0.04* 33.4 16.0 2.1 to 64.7 0.04* 31.3 12.5 6.8 to 55.8 0.01*
FEV1/FVC −0.1 0.3 −0.6 to 0.4 0.78 −0.4 0.2 −0.8 to −0.0 0.03* −0.3 0.2 −0.6 to 0.0 0.07
#
γ-T 2289 2237 4526
FEV1 −80.0 37.7 −154.0 to −6.0 0.03* −78.0 47.1 −170.3 to 14.3 0.10
# −73.7 29.5 −131.6 to −15.8 0.01*
FVC −106.7 42.8 −190.7 to −22.7 0.01* −107.8 54.8 −215.3 to −0.4 0.05* −97.0 34.1 −163.9 to −30.0 0.005*
FEV1/FVC 0.3 0.5 −0.8 to 1.4 0.59 0.2 0.7 −1.1 to 1.5 0.74 0.2 0.4 −0.6 to 1.1 0.58
(Linear regression analysis at year 0 of the CARDIA study).
aAdjustments: center, age, age2, height, height2, sex, BMI, smoking status and ever asthma.
bAdjustments: center, age, age2, height, height2, sex, BMI, smoking status and ever asthma, race.
cβ is the difference in mL of FEV1, mL of FVC or % FEV1/FVC per 10 μM tocopherol.













Table 4 Association of γ-T with lung spirometry (within quartiles of α-tocopherol) at year 0 of CARDIA
Quartiles of α-T N Difference in FEV1
per 10 μM γ-T
P value Difference in FVC
per 10 μM γ-T
P value Difference in FEV1/FVC (%)
per 10 μM γ-T
P value
(μM) β β β
A BLACKS
5.73-17.21 596 −207.3 0.05* −174.8 0.16 −1.0 0.55
17.22-20.11 522 8.2 0.94 −119.7 0.32 2.4 0.10
20.12-23.80 407 −103.4 0.38 −158.6 0.25 0.8 0.58
23.81-84.80 271 −103.9 0.06 −81.3 0.22 −0.8 0.29
B WHITES
5.73-17.21 317 −282.8 0.10# −265.7 0.17 −1.2 0.60
17.22-20.10 389 −195.0 0.19 −271.3 0.14 0.7 0.71
20.11-23.80 500 −80.7 0.44 −42.3 0.73 −1.2 0.42
23.81-84.80 604 −80.1 0.25 −164.1 0.05* 0.9 0.34
C ALL PARTICIPANTS
5.73-17.21 913 −208.3 0.02* −171.3 0.11# −1.1 0.42
17.22-20.10 911 −58.7 0.50 −175.1 0.09# 2.0 0.09#
20.11-23.80 907 −82.4 0.29 −82.4 0.37 −0.3 0.77
23.81-84.80 875 −95.1 0.02* −107.0 0.03* −0.2 0.73
Year 0 of CARDIA: Adjustments: center, age, age2, height, height2, sex, BMI, smoking status.













Table 5 Association of α-T with lung spirometry (within quartiles of γ-tocopherol) at year 0 of CARDIA
Quartiles of γ-T N Difference in FEV1
per 10 μM α-T
P value Difference in FVC
per 10 μM α-T
P value Difference in FEV1/FVC (%)
per 10 μM α-T
P value
(μM) β β β
A BLACKS
0.00-3.59 375 73.8 0.03* 62.3 0.11# 0.6 0.20
3.60-4.69 432 −55.7 0.29 1.0 0.99 −1.3 0.05*
4.70-5.99 442 60.7 0.24 37.8 0.52 0.7 0.33
6.00-68.35 547 25.2 0.49 43.8 0.31 −0.3 0.55
B WHITES
0.00-3.59 538 −13.1 0.53 19.6 0.44 −0.6 0.04*
3.60-4.69 451 27.3 0.44 −18.1 0.65 −0.2 0.64
4.70-5.99 463 10.2 0.79 22.1 0.64 −0.1 0.80
6.00-68.35 358 37.0 0.34 84.4 0.05* −0.7 0.18
C ALL PARTICIPANTS
0.00-3.59 913 11.8 0.51 29.9 0.16 −21.7 0.39
3.60-4.69 883 −33.8 0.24 −12.8 0.70 −0.5 0.20
4.70-5.99 905 24.9 0.42 17.9 0.63 0.3 0.51
6.00-68.35 905 20.7 0.43 50.7 0.10# −0.5 0.16
Nonasthmatics, Year 0 of CARDIA (Adjustments: center, age, age2, height, height2, sex, BMI, smoking status).













































































































Figure 1 Highly-elevated γ-tocopherol associates with reduced FEV1 and FVC at ages 21–55. We a priori defined γ-tocopherol groups to
model the average Western European/Asian γ-tocopherol levels (1–2 μM) (Additional file 2: Table S2) [4] and to model the average U.S.A. γ-tocopherol
levels (3–4.8 μM and 4.9-10 μM) (Table 2 and Additional file 2: Table S2) [1-4]. We also defined a priori a γ-tocopherol group as >10 μM to model the
5-fold higher γ-tocopherol observed in our animal studies [19]. In study year 5, the four γ-tocopherol categories represented from lowest to highest
γ-tocopherol groups of CARDIA: 36 (1.1%), 1291 (38.0%), 2015 (59.3%), and 58 (1.7%) participants. To examine the association of γ-tocopherol with FEV1,
FVC and FEV1/FVC as a function of participant age, we used generalized estimating equations (GEE) to analyze spirometry and tocopherol as described
in the Methods and Additional file 3: Methods. For GEE models, included were the following variables: center, race, exam year, height, height2,
sex, BMI, smoking status, asthma group, average α-tocopherol concentration, 3 dummy variables representing the 4 γ-tocopherol groups, and
the interactions of the four γ-tocopherol groups with age. The number of readings used for analysis for low, moderate, moderate-high, and
highly-elevated γ-tocopherol groups were: (A, D, G) 93, 3493, 5381 and 160, respectively, for all participants; (B, E, H) 80, 2696, 4281, and 123,
respectively, for non-asthmatics; and (C, F, I) 13, 797, 1100 and 37, respectively, for self-reported ever asthmatics. A missing data point in C, F
and I at age 21–27 in the low γ-tocopherol group occurred because the participants at this age did not have this level of γ-tocopherol in the
self-reported asthmatics. Nevertheless, for the self-reported asthmatics, the high γ-tocopherol group at age 21–27 was significantly different
than the groups with moderate levels of γ-tocopherol. *, p < 0.05 compared to the other groups at 21–27 years old.
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in previous reports (Additional file 2: Table S2) are 4–
7 μM γ-tocopherol [19]. To model the average USA
γ-tocopherol levels, two groups were defined a priori
as moderate (3–4.8 μM, the average published for
NHANES in the U. S.A. [19]) and moderate-high (4.9-
10 μM, [1-4]). In addition, because a 5-fold higher
γ-tocopherol in our animal studies reduced lung respon-
siveness, another group at >10 μM γ-tocopherol was de-
fined a priori to model 5-fold higher γ-tocopherol than the
average European plasma γ-tocopherol group (Figure 1).
Analysis was performed separately for non-asthmatics
and for the participants with self-reported ever having
asthma, because in Table 1, 20% of the participants re-
ported ever having asthma and because our previous
studies showed that γ-tocopherol reduced lung function
of mice with experimental asthma [4,12,13]. In this ana-
lysis for participants at ages 21–55, we used spirometry
from study years 5, 10, 20 and 25 and the tocopherol
concentrations from study years 0, 7 and 15. We ad-
dressed the data limitation of lack of concordant spirom-
etry and tocopherol data after year 0 of CARDIA by
analyzing with GEE and averaging the CARDIA year 0, 7
and year 15 serum γ-tocopherol concentrations for each
individual study participant because individuals tended
to maintain their tocopherol relative positions over 15
years as analyzed by covariance of slope and intercept
parameters (described in detail in the Manuscript
Additional file 3: Methods). Also, the average of the three
tocopherol measures reflects the long term exposure of
the tocopherol. To limit the potential effects of opposing
functions of very high α-tocopherol on spirometric pa-
rameters [13], and because it was determined in the cross-
sectional analysis at CARDIA study year 0 that there were
opposing effects of α-tocopherol and γ-tocopherol, it was
determined a priori to include participants with a serum
α-tocopherol level less than 37.1 μM because it is two
standard deviations above the mean concentration of
serum α-tocopherol in the 20–39 year age group from
the U.S. National Health and Nutrition Examination
Survey (NHANES) [19]. In addition, the average plasma
α-tocopherol concentrations are about the same among
several countries (Additional file 2: Table S2) [1,4].
After exclusions primarily for individuals who were
missing data for tocopherol, spirometry or covariate at
follow-up years (n = 623) and exclusion of a few indi-
viduals with very high serum α-tocopherol levels (over
37.1 μM) (n = 146), there were 3757 participants from
years 5, 10, 20 and 25 of CARDIA for analysis. Because
our analysis of this CARDIA cohort at year 0 revealed
similar associations of α-tocopherol and γ-tocopherol
in both races, we did not stratify the data by race in this
analysis, but instead we adjusted for race to maintain
the sample size of the highest and lowest γ-tocopherolgroups. A GEE analysis was also performed with per-
cent predicted values for FEV1 and the statistical out-
comes were the same (data not shown).
Statistical data for Figure 1 is as follows: For 21–27
year old CARDIA participants, the FEV1 for the highly-
elevated γ-tocopherol group is lower than the low, mod-
erate, and moderate-high γ-tocopherol groups by: A)
317 mL (p = 0.006), 284 mL (p = 0.0003), and 263 mL
(p = 0.0008), respectively, for all CARDIA participants
(non-asthmatics and those who self-reported that they ever
had asthma); B) 255 mL (p = 0.04), 213 mL (p = 0.01) and
175 mL (p = 0.03), respectively, for non-asthmatics; and C)
460 mL (p = 0.08), 475 mL (p < 0.009), and 517 mL
(p = 0.004), respectively, for self-reported ever asth-
matics. For 21–27 year old CARDIA participants, the
FVC for the highly-elevated γ-tocopherol group is
lower than the low, moderate, and moderate-high γ-
tocopherol groups by: D) 322 mL (p = 0.01), 263 mL
(p = 0.004), and 254 mL (p = 0.005), respectively, for all
participants; E) 263 mL (p = 0.05), 160 mL (p = 0.08) and
156 mL (p = 0.08), respectively, for non-asthmatics; and F)
357 mL (p = 0.22), 568 mL (p = 0.009) and 545 mL
(p = 0.01), respectively, for self-reporting ever asthmatics.
For FEV1, the tests for interaction of the continuous age
variable for the highly-elevated γ-tocopherol group
compared to the low, moderate and moderate-high
γ-tocopherol groups were as follows: A) p = 0.07, p = 0.12,
and p = 0.11, respectively, in all participants; B) p = 0.23,
p = 0.45 and p = 0.58, respectively, in the non-
asthmatics; and C) p = 0.21, p = 0.10 and p = 0.05, re-
spectively, in those with “ever asthma”. For FVC, the
tests for interaction of the continuous age variable for
the highly-elevated γ-tocopherol group compared to
the low, moderate and moderate-high γ-tocopherol groups
were as follows: D) p = 0.60, p = 0.89, and p = 0.63, respect-
ively, for all participants; E) p = 0.98, p = 0.25 and p = 0.65,
respectively, for non-asthmatics; and F) p = 0.53, p = 0.31
and p = 0.22, respectively, for those reporting “ever
asthma”.
Figure 1 presents data for all CARDIA participants
and also stratifies results by asthma status. For the 21–
27 year olds, FEV1 for the highly-elevated γ-tocopherol
group was significantly lower than the low, moderate, or
moderate-high γ-tocopherol groups that modeled the
average European/Asian and USA plasma γ-tocopherol
levels (Figure 1A-C). Similarly, in the 21–27 year olds,
FVC of the highly-elevated γ-tocopherol group was sig-
nificantly lower than the other γ-tocopherol groups
(Figure 1D-F). For ages 21–55, there was no difference
in slopes of FEV1 and FVC (NS test for interaction with
age). Therefore, because FEV1 and FVC for the highly-
elevated γ-tocopherol group was significantly lower
than the other γ-tocopherol groups at the age 21–27
and then there was no difference among the slopes of
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elevated γ-tocopherol group was lower than the other
γ-tocopherol groups (Figure 1A-F). The analysis of
FEV1/FVC resulted in no significant differences among
the γ-tocopherol groups (Figure 1G-I).
Discussion
In CARDIA, α-tocopherol positively associated with and
γ-tocopherol negatively associated with spirometric pa-
rameters. Moreover, in the tocopherol isoform quartile
analysis, the associations of tocopherols with FEV1 were
most evident when the concentration of the opposing
tocopherol was low and causing the least competing op-
posing effects. In modeling average γ-tocopherol con-
centrations for the USA and European/Asian countries,
a 5-fold higher γ-tocopherol associated with reduced
FEV1 and FVC in the 21–27 year olds and this reduction
was sustained to age 55.
Based on our cross-sectional results for blacks
with −80 mL FEV1/10 μM γ-tocopherol in Table 3, the
study participants at two standard deviations above the
mean of serum γ-tocopherol have about a 77 mL lower
FEV1, compared with the participants at two standard de-
viations below the mean serum γ-tocopherol. Similarly,
study participants with the highest range of γ-tocopherol
would have about a 100 mL lower FVC. These reduc-
tions in spirometric parameters are even higher for par-
ticipants with the lowest quartile of α-tocopherol because
in these participants, there is a −207 to −282 mL FEV1/
10 μM γ-tocopherol for blacks and white, respectively, in
Table 4.
There was also a difference in spirometry parameters
over the range of α-tocopherol concentrations. The
two standard deviations above and below the average
α-tocopherol in black CARDIA participants was 9.15-
30.27 μM at year 0 of CARDIA. The cross-sectional
analysis indicates that each 10 μM higher α-tocopherol
associates with 40.4 mL higher FVC in blacks. There-
fore, a study participant at the higher range of α-
tocopherol (30.27 μM) should have about 85 mL
greater FVC than an individual at the lower level. This
is similar in magnitude to another report indicating
that an estimated intake of 2 mg/day of vitamin E in
foods in the United Kingdom associates with a 39 mL
increase in FEV1 [20]. These magnitudes are also simi-
lar to that reported for vitamin C. Vitamin C intake
(100 mg/day) is reported to associate with a 22–42 mL
increase in FEV1 and a 25–80 ml increase in FVC [21].
A strength of this study is the cohort size for analysis
of effects of tocopherols with the least amount of the
opposing tocopherol. The limitation that in years 7–25,
spirometry data and plasma for tocopherol analysis were
not collected at the same time was addressed using GEE
analysis. The GEE analysis indicates that at ages 21–55,highly-elevated levels of serum γ-tocopherol associated
with significantly lower FEV1 and FVC. Furthermore,
since the slopes in spirometry with age were not differ-
ent, it suggests that the reduction in FEV1 and FVC as-
sociated with tocopherol may be achieved before age 21.
This finding is consistent with potential vitamin E regu-
lation of human lung development because maternal α-
tocopherol positively associates with fetal length and
with FEV1 in 5 year old children in a report in the
United Kingdom [22,23]. The γ-tocopherol-associated
decreases in FEV1 and FVC before age 21 may occur
during lung responses to environmental pollutants, aller-
gens, or infections because tocopherols can directly
regulate PKC [3,4,12,13]. Tocopherols have an effect on
plateau spirometry parameters. This effect may be rele-
vant for spirometry parameters later in life. Furthermore,
based on the about 2% prevalence with highly-elevated
(>10 μM) serum γ-tocopherol in adults in CARDIA and
the U.S. 2011 census of adults, we expect that the 350–
570 milliliters lower FEV1 or FVC occurs in up to 4.5
million adults in the population. This is a clinically sig-
nificant volume because it corresponds to 9 to 15 years
of decline in lung function with aging [24].
The γ-tocopherol association with reduced FEV1 and
FVC was exacerbated in the asthmatic group, resulting
in participants having 350–570 mL lower FEV1 or FVC
in the highly-elevated γ-tocopherol group as compared
to the low to moderate γ-tocopherol groups at ages 21–
27. This 10 to 17% decrease in FEV1 is similar to the 5-
10% reduction in FEV1 reported for other environmental
factors. For example, individuals with occupational aller-
gen exposure have a 5-8% decrease in FEV1 and this de-
crease is associated with dyspnea, chest tightness,
chronic bronchitis, and chronic cough [25]. It is also re-
ported that responders to particulate matter have a 2 to
6% decrease in FEV1 [26], responders to cold or exercise
have a 5 to 11% decrease in FEV1 [27] and responders to
house dust mite or dog/cat dander have a 2-8% decrease
in FEV1 [28].
Conclusion
In summary, our study is the first to report that in humans,
there are opposing associations for α-tocopherol and γ-
tocopherol with spirometric parameters. α-tocopherol asso-
ciates with higher spirometric parameters and γ-tocopherol
associates with lower spirometric parameters. Moreover,
our analysis suggests that the opposing effects of an isoform
of tocopherol occur in participants with the lowest
range of the opposing isoform of tocopherol. These as-
sociations of tocopherol isoforms with spirometric pa-
rameters in humans are consistent with the mechanistic
studies of opposing functions for α-tocopherol and γ-






















Figure 2 Participant flow chart. Of the 5115 participants recruited
into CARDIA, 1 dropped out. Of the 5114 CARDIA remaining
participants, 4827 participated in YALTA and had year 0 tocopherol
measurements in the CARDIA database. Of the 4827, participants
were excluded from the analysis if they were missing data for
spirometry at year 0 (n = 243), missing data for smoking, body mass
index, or height (n = 46) or self-reported having chronic obstructive
pulmonary disease (COPD) (n = 12) (Figure 2). After these exclusions,
there were 4526 participants in the analytic sample. Of these, 920
study participants self-reported as ever having asthma and/or being
treated for asthma at any of the 7 visits (Table 1). For our analysis,
there were 4,526 participants after excluding participants with COPD
or excluding participants that lacked data for tocopherol levels,
spirometry, BMI, height or smoking.
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Cohort description
CARDIA is a multi-center longitudinal cohort study
designed to examine the risk factors for cardiovascular
disease in young adults enrolled at 18–30 years [29-31].
By design, the study enrolled 5,114 participants in equal
subgroups of race (black or white), and gender. Partici-
pants were assessed at year 0 (1985–1986) and years 2,
5, 7, 10, 15, and 20. Young Adult Longitudinal Trends
in Antioxidants (YALTA), an ancillary CARDIA study,
measured serum tocopherols from blood samples of
fasting participants in years 0, 7, and 15 of the study
[32,33]. After exclusions in Figure 2, there were 4,526
participants.
Spirometry
The spirometry measurements FEV1 and FVC were at years
0, 2, 5, 10, and 20 as described in the Additional file 3.American Thoracic Society (ATS)/European Respiratory
Society (ERS) guidelines were followed to ensure quality
control and testing procedures [34].Tocopherol analysis
Tocopherols at years 0, 7, and 15 of the study were ex-
tracted from the serum and analyzed by high pressure li-
quid chromatography (HPLC) [35] as described in the
Additional file 3.Statistical analyses
Details of each statistical analysis are in the Manuscript
Additional file 3. Briefly, multivariable linear regres-
sions were performed at study year 0 to determine the
association between tocopherol concentrations and
spirometry. Due to significant differences in tocopherol
concentrations (p < 0.0001) by race, data were either
stratified by race or adjusted for race as indicated in the
tables and figures. To analyze associations of opposing
effects of tocopherol isoforms, the association of each
isoform was analyzed by strata based on quartiles of the
opposing tocopherol using the SAS (Cary, NC, USA)
GLM procedure.
To examine the association of γ-tocopherol with spir-
ometry as a function of participant age, we used general-
ized estimating equations (GEE) as described in the
Additional file 3 and figure legend. We used GEE ana-
lysis for FEV1, FVC and FEV1/FVC as a function of the
age groups for presentation in the figure and also did
analysis treating age as a continuous variable as de-
scribed in the Additional file 3. The GEE analysis was
also performed with percent predicted values for FEV1
and the statistical outcomes were the same (data not
shown).Additional files
Additional file 1: Table S1. The association of α-tocopherol (α-T) and
γ-tocopherol (γ-T) with lung spirometry with adjustment for other
tocopherol isoform. (Linear regression analysis at year 0 of the CARDIA
study).
Additional file 2: Table S2. Plasma γ-tocopherol (γT) and α-tocopherol
(αT) in several countries.
Additional file 3: Detailed Methods.Abbreviations
CARDIA: Coronary Artery Risk Development in Young Adults; COPD: Chronic
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